Patients' and urologists' preferences for prostate cancer treatment: A discrete choice experiment

British Journal of Cancer

Volumn 109, Issue 3, 2013, Pages 633-640

  De Bekker Grob, E W ^a   Bliemer, M C J ^b   Donkers, B ^c   Essink Bot, M L ^d   Korfage, I J ^a   Roobol, M J ^a   Bangma, C H ^a   Steyerberg, E W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ANXIETY; ARTICLE; CANCER RADIOTHERAPY; CANCER SURGERY; DEPRESSION; ERECTILE DYSFUNCTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT DECISION MAKING; PATIENT PREFERENCE; PRIORITY JOURNAL; PROSTATE CANCER; QUESTIONNAIRE; TREATMENT RESPONSE; URINE INCONTINENCE; UROLOGIST;

AGED; DECISION MAKING; ERECTILE DYSFUNCTION; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PATIENT PREFERENCE; PHYSICIAN'S PRACTICE PATTERNS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; URINARY INCONTINENCE;

EID: 84883160505     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.370     Document Type: Article

References (39)

1. Aning JJ, Wassersug RJ, Goldenberg SL (2012) Patient preference and the impact of decision-making aids on prostate cancer treatment choices and post-intervention regret. Curr Oncol 19: S37-S44.
2. Ashcroft DM, Seston E, Griffiths CE (2006) Trade-offs between the benefits and risks of drug treatment for psoriasis: a discrete choice experiment with U.K. dermatologists. Br J Dermatol 155: 1236-1241.
3. Berchi C, Dupuis JM, Launoy G (2006) The reasons of general practitioners for promoting colorectal cancer mass screening in France. Eur J Health Econ 7: 91-98.
4. Bishop AJ, Marteau TM, Armstrong D, Chitty LS, Longworth L, Buxton MJ, Berlin C (2004) Women and health care professionals' preferences for Down's syndrome screening tests: a conjoint analysis study. BJOG 111: 775-779.
5. Damber JE, Khatami A (2005) Surgical treatment of localized prostate cancer. Acta Oncol 44: 599-604.
6. de Bekker-Grob EW, Essink-Bot ML, Meerding WJ, Koes BW, Steyerberg EW (2009) Preferences of GPs and patients for preventive osteoporosis drug treatment: a discrete-choice experiment. Pharmacoeconomics 27: 211-219.
7. de Bekker-Grob EW, Hol L, Donkers B, van Dam L, Habbema JD, van Leerdam ME, Kuipers EJ, Essink-Bot ML, Steyerberg EW (2010) Labeled versus unlabeled discrete choice experiments in health economics: an application to colorectal cancer screening. Value Health 13: 315-323.
8. de Bekker-Grob EW, Ryan M, Gerard K (2012) Discrete choice experiments in health economics: a review of the literature. Health Econ 21: 145-172.
9. Dolan P (1997) Modeling valuations for EuroQol health states. Med Care 35: 1095-1108.
10. Emberton M (2010) Medical treatment of benign prostatic hyperplasia: physician and patient preferences and satisfaction. Int J Clin Pract 64: 1425-1435.
11. Gillitzer R, Thuroff JW (2003) Technical advances in radical retropubic prostatectomy techniques for avoiding complications. Part II: vesico-urethral anastomosis and nerve-sparing prostatectomy. BJU Int 92: 178-184.
12. Hall J, Fiebig DG, King MT, Hossain I, Louviere JJ (2006) What influences participation in genetic carrier testing? Results from a discrete choice experiment. J Health Econ 25: 520-537.
13. Hensher DA, Rose JM, Greene WH (2005) Applied choice analysis: a primer. Cambridge University Press: Cambridge, UK.
14. Kim SI, Kang JY, Lee HW, Seong do H, Cho JS (2011) A survey conducted on patients' and urologists' perceptions of benign prostatic hyperplasia. Urol Int 86: 278-283.
15. Klotz L (2006) Active surveillance versus radical treatment for favorable-risk localized prostate cancer. Curr Treat Options Oncol 7: 355-362.
16. Korfage IJ, Essink-Bot ML, Borsboom GJ, Madalinska JB, Kirkels WJ, Habbema JD, Schroder FH, de Koning HJ (2005) Five-year follow-up of health-related quality of life after primary treatment of localized prostate cancer. Int J Cancer 116: 291-296.
17. Lancsar E, Louviere J (2008) Conducting discrete choice experiments to inform healthcare decision making: a user's guide. Pharmacoeconomics 26: 661-677.
18. Lee A, Gin T, Lau AS, Ng FF (2005) A comparison of patients' and health care professionals' preferences for symptoms during immediate postoperative recovery and the management of postoperative nausea and vomiting. Anesth Analg 100: 87-93.
19. Mantovani LG, Monzini MS, Mannucci PM, Scalone L, Villa M, Gringeri A (2005) Differences between patients', physicians' and pharmacists' preferences for treatment products in haemophilia: a discrete choice experiment. Haemophilia 11: 589-597.
20. Montgomery AA, Fahey T (2001) How do patients' treatment preferences compare with those of clinicians? Qual Health Care 10(Suppl 1): i39-i43.
21. Pearmain D, Swanson J, Kroes E, Bradley M (1991) Stated Preferences Techniques: A Guide To Practice. The Hague, Steer Davis Gleave and Hague Consulting Group: Hagues, The Netherlands.
22. Penson DF, McLerran D, Feng Z, Li L, Albertsen PC, Gilliland FD, Hamilton A, Hoffman RM, Stephenson RA, Potosky AL, Stanford JL (2008) 5-year urinary and sexual outcomes after radical prostatectomy: results from the Prostate Cancer Outcomes Study. J Urol 179: S40-S44.
23. Potosky AL, Davis WW, Hoffman RM, Stanford JL, Stephenson RA, Penson DF, Harlan LC (2004) Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst 96: 1358-1367.
24. Ramsey SD, Zeliadt SB, Fedorenko CR, Blough DK, Moinpour CM, Hall IJ, Smith JL, Ekwueme DU, Fairweather ME, Thompson IM, Keane TE, Penson DF (2011) Patient preferences and urologist recommendations among local-stage prostate cancer patients who present for initial consultation and second opinions. World J Urol 29: 3-9.
25. Reed Johnson F, Lancsar E, Marshall D, Kilambi V, Muhlbacher A, Regier DA, Bresnahan BW, Kanninen B, Bridges JF (2013) Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. Value Health 16: 3-13.
26. Roobol MJ, Schroder FH (2003) European Randomized Study of Screening for Prostate Cancer: achievements and presentation. BJU Int 92(Suppl 2): 117-122.
27. Ryan M (2004) Discrete choice experiments in health care. BMJ 328: 360-361.
28. Salkeld G, Solomon M, Butow P, Short L (2005) Discrete-choice experiment to measure patient preferences for the surgical management of colorectal cancer. Br J Surg 92: 742-747.
29. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Maattanen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360: 1320-1328.
30. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Paez A, Maattanen L, Bangma CH, Aus G, Carlsson S, Villers A, Rebillard X, van der Kwast T, Kujala PM, Blijenberg BG, Stenman UH, Huber A, Taari K, Hakama M, Moss SM, de Koning HJ, Auvinen A (2012) Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 366: 981-990.
31. Stanford JL, Feng Z, Hamilton AS, Gilliland FD, Stephenson RA, Eley JW, Albertsen PC, Harlan LC, Potosky AL (2000) Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA 283: 354-360.
32. Street DJ, Burgess L, Louviere JJ (2005) Constructing optimal and nearly optimal stated choice experiments. Intern J Res Marketing 22: 459-470.
33. Swait J, Louviere J (1993) The role of the scale parameter in the estimation and comparison of multinomial logit models. J Marketing Res 30: 305-314.
34. Szeinbach SL, Harpe SE, Williams PB, Elhefni H (2008) Testing for allergic disease: parameters considered and test value. BMC Fam Pract 9: 47.
35. Train KE (2003) Discrete Choice Methods With Simulations. Cambridge University Press: Cambridge, UK.
36. van den Bergh RC, Essink-Bot ML, Roobol MJ, Schroder FH, Bangma CH, Steyerberg EW (2010) Do anxiety and distress increase during active surveillance for low risk prostate cancer? J Urol 183: 1786-1791.
37. van Tol-Geerdink JJ, Stalmeier PF, van Lin EN, Schimmel EC, Huizenga H, van Daal WA, Leer JW (2006) Do patients with localized prostate cancer treatment really want more aggressive treatment? J ClinOncol 24: 4581-4586.
38. van Tol-Geerdink JJ, Willem Leer J, Weijerman PC, van Oort IM, Vergunst H, van Lin EN, Alfred Witjes J, Stalmeier PF (2013) Choice between prostatectomy and radiotherapy when men are eligible for both: a randomized controlled trial of usual care vs decision aid. BJU Int 111: 564-573.
39. Zeliadt SB, Ramsey SD, Penson DF, Hall IJ, Ekwueme DU, Stroud L, Lee JW (2006) Why do men choose one treatment over another?: a review of patient decision making for localized prostate cancer. Cancer 106: 1865-1874.